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Glutaminyl cyclase is a zinc-dependent metallo-enzyme that catalyzes the formation of 
pyroglutamic acid (pGlu) from the N-terminal glutaminyl and glutamyl precursors of several 
bioactive peptides and proteins. Owing to the involvement in the formation of pGlu-modified 
amyloid peptides, human glutaminyl cyclase (hQC) represents a validated target for the treatment of 
neurodegenerative pathologies like Alzheimer disease (AD) and various forms of dementia 
including familial British and Danish dementias (1). Amyloid  (A ) peptide, bearing a N-terminal 
pyroglutamate in position 3 [A N3(pE)], has been reported as major N-truncated, modified 
constituent of intracellular, extracellular and vascular A  deposits in AD brain tissue (2). A N3(pE) 
forms soluble oligomers that favor the aggregation processes, also promoting the aggregation of 
nonmodified peptides (2).  
Various attempts to express hQC in Escherichia coli resulted in serious drawbacks in terms of ease 
of production and very low yield of purified protein. To overcome these problems, we generated a 
hQC variant in which two surface residues implicated in protein aggregation were mutated into 
glutamic acids resulting in a soluble protein variant that provided very high protein yields in the 
bacterial expression system (~ 50 mg L-1 bacterial culture) (3). Kinetic and structural analysis on 
this hQC variant revealed that it has conserved properties and structure compared to those of the 
native enzyme. Here, we are reporting the X-ray crystallographic screening of a library of amino-
thiadiazole derivatives formerly developed towards a parasite enzyme target belonging to the folate 
pathway (4). Some of these molecules have shown good activities when tested in kinetic inhibition 
assays toward our engineered variant. Twelve structures of enzyme-inhibitor complexes have been 
determined providing key information about the interactions guiding the recognition of these 
innovative molecules in the hQC active site. Furthermore, the binding mode of these compounds, 
driven by the coordination of the amino-thiadiazole molecular core to the Zn(II) ion in the catalytic 
cavity, is quite peculiar and it does not resemble any inhibitor reported to date in the literature. The 
structural information achieved during this X-ray crystallographic screening will drive us in the 
development of more potent hQC inhibitors aiming to find new molecular tools for the treatment of 
neurodegenerative pathologies like Alzheimer disease. 
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